Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-08-27 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-08-27 English
VOLUNTARY ANNOUNCEMENT-MEDICAL SERVICES COOPERATION FRAMEWORK AGREEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding a Medical Services Cooperation Framework Agreement. It details the terms, parties involved, annual caps, and internal approval procedures. The document is an announcement of a specific agreement and related transactions, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial analysis. It is also not a report publication announcement since it contains substantive information about the agreement itself. The content fits best under a general regulatory announcement category related to compliance and disclosure of connected transactions. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-27 English
ANNOUNCEMENT ON CAPITAL INCREASE IN YANKUANG FINANCE COMPANY
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase transaction involving Yanzhou Coal Mining Company Limited and its subsidiary Yankuang Finance Company. It details the transaction terms, parties involved, approvals, and regulatory compliance references. The text includes no financial statements or detailed financial analysis but focuses on the disclosure of a corporate financing event. It is not a full financial report, audit report, or earnings release. The document is a formal announcement of a capital increase, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is not a brief report publication announcement or a simple regulatory filing. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2021-08-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-08-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-08-27 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report Classification · 95% confidence The document is an announcement of interim results for the six months ended June 30, 2021, for CStone Pharmaceuticals. It contains detailed financial highlights, business highlights, commercial efforts, clinical successes, and pipeline updates. The presence of unaudited condensed consolidated results, comparative figures for the prior period, and substantive financial data indicates this is a comprehensive financial report for a period shorter than a full fiscal year. The document is lengthy (15,000 characters) and contains actual financial statements and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.